| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T8 |
0-87 |
Sentence |
denotes |
Neurological manifestations are increasingly reported in a subset of COVID-19 patients. |
| T9 |
88-289 |
Sentence |
denotes |
Previous infections related to coronaviruses, namely Severe Acute Respiratory Syndrome (SARS) and Middle Eastern Respiratory Syndrome (MERS) also appeared to have neurological effects on some patients. |
| T10 |
290-515 |
Sentence |
denotes |
The viruses associated with COVID-19 like that of SARS enters the body via the ACE-2 receptors in the central nervous system, which causes the body to balance an immune response against potential damage to nonrenewable cells. |
| T11 |
516-594 |
Sentence |
denotes |
A few rare cases of neurological sequelae of SARS and MERS have been reported. |
| T12 |
595-797 |
Sentence |
denotes |
A growing body of evidence is accumulating that COVID-19, particularly in severe cases, may have neurological consequences although respiratory symptoms nearly always develop prior to neurological ones. |
| T13 |
798-918 |
Sentence |
denotes |
Patients with preexisting neurological conditions may be at elevated risk for COVID-19-associated neurological symptoms. |
| T14 |
919-1131 |
Sentence |
denotes |
Neurological reports in COVID-19 patients have described encephalopathy, Guillain-Barré syndrome, myopathy, neuromuscular disorders, encephalitis, cephalgia, delirium, critical illness polyneuropathy, and others. |
| T15 |
1132-1275 |
Sentence |
denotes |
Treating neurological symptoms can pose clinical challenges as drugs that suppress immune response may be contraindicated in COVID-19 patients. |
| T16 |
1276-1384 |
Sentence |
denotes |
It is possible that in some COVID-19 patients, neurological symptoms are being overlooked or misinterpreted. |
| T17 |
1385-1556 |
Sentence |
denotes |
To date, neurological manifestations of COVID-19 have been described largely within the disease trajectory and the long-term effects of such manifestations remain unknown. |
